A Paradigm Shift in Neural Regeneration: Leveraging MoA-Driven Biomarkers & Oncology Precedents for Accelerated Clinical Success

• Novel Target Discovery and AI Platform: Unlocking deeper therapeutic insights through the AI-driven discovery of neuroregenerative targets (encompassing neurogenesis, neuroprotection, and synaptogenesis) and the identification of mechanistically driven biomarkers
• First-in-Human Translation in ALS: Translating insights from a First-in-Human (FIH) study evaluating a novel neuroregenerative therapeutic for Amyotrophic Lateral Sclerosis (ALS), while rethinking the clinical utility and limitations of peripheral blood Neurofilament Light (NfL) chain as a general structural marker
• MoA-Specific Biomarkers in Companion Canine Patients: Showcasing the robust translational value of proprietary, mechanism-specific biomarker(s), which directly correlate with disease severity across diverse real-world companion canine patients suffering from natural neurodegenerative diseases
• Strategic Imperatives: Defining actionable clinical development and biomarker strategies to bridge the translational gap, successfully delivering genuine, disease-modifying therapies to patients

Speakers:

Han Sungho

Founder & Chief Executive Officer

GENUV, Inc.